Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan;132(1):93-97.
doi: 10.1213/ANE.0000000000004752.

Incidence of Anaphylaxis to Sugammadex in a Single-Center Cohort of 19,821 Patients

Mark A Burbridge  1
Affiliations
Case Reports

Incidence of Anaphylaxis to Sugammadex in a Single-Center Cohort of 19,821 Patients

Mark A Burbridge. Anesth Analg. 2021 Jan.

Abstract

Background: Sugammadex is a modified cyclodextrin that is being increasingly used in anesthetic practice worldwide for the reversal of the aminosteroid neuromuscular blockers rocuronium and vecuronium. Its safety profile, however, is incompletely understood. One such aspect is the incidence of anaphylactic reactions that occur after its administration. While several case reports exist in the literature, there is a paucity of information on the actual incidence of anaphylactic reactions.

Methods: A single-center retrospective chart review identified patients who experienced anaphylaxis to sugammadex in the institutional electronic medical record system. These charts were then reviewed to determine whether the etiology of anaphylaxis was sugammadex administration.

Results: Two patients experienced anaphylaxis to sugammadex, which occurred in a single institution cohort of 19,821 patients who received 23,446 total doses. This rate is markedly lower than the 1/300 that the manufacturer's package insert states and also lower than the 1/2500 that the only other large cohort study performed has reported.

Conclusions: The incidence of anaphylaxis to sugammadex in this cohort of patients was 2 of 19,821 patients, who received a total of 23,446 doses.

PubMed Disclaimer

Comment in

References

    1. Ue KL, Kasternow B, Wagner A, Rutkowski R, Rutkowski K. Sugammadex: an emerging trigger of intraoperative anaphylaxis. Ann Allergy Asthma Immunol. 2016;117:714–716.
    1. Meistelman C, Donati F. Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia?. Curr Opin Anaesthesiol. 2016;29:462–467.
    1. Takazawa T, Mitsuhata H, Mertes PM. Sugammadex and rocuronium-induced anaphylaxis. J Anesth. 2016;30:290–297.
    1. Bridion (sugammadex) [package insert]. 2015.Greenville, NC: Merck Sharp & Dohme Corp;
    1. O’Donnell R, Hammond J, Soltanifar S. A confirmed case of sugammadex-induced anaphylaxis in a UK hospital. BMJ Case Rep. 2017:pii: bcr-2017-220197.

Publication types